Evaluating the Efficacy of a Mobile App (Drinks:Ration) and Personalized Text and Push Messaging to Reduce Alcohol Consumption in a Veteran Population: Protocol for a Randomized Controlled Trial.
Evaluating the Efficacy of a Mobile App (Drinks:Ration) and Personalized Text and Push Messaging to Reduce Alcohol Consumption in a Veteran Population: Protocol for a Randomized Controlled Trial.
复制标题
DOI：
10.2196/19720
复制
发表时间：
2020-10-02
影响因子：
1.7
通讯作者：
Murphy D
中科院分区：
文献类型：
--
作者：
Leightley D;Rona RJ;Shearer J;Williamson C;Gunasinghe C;Simms A;Fear NT;Goodwin L;Murphy D
英国武装部队的酒精滥用率高于一般人群。先前的研究表明，通过智能手机提供的干预措施在促进自我监测酒精使用方面是有效的，在减少酒精消费方面具有实用性，并且具有广泛的影响力。这项单盲随机对照试验（RCT）旨在评估通过智能手机应用程序（Drinks：Ration）提供的28天简短酒精干预在减少基线和3个月随访之间每周自我报告的酒精消费量方面的有效性。在这个双臂，单盲随机对照试验中，一个智能手机应用程序，包括旨在提高参与者的动机和个性化消息的互动功能，与一个智能手机应用程序，只提供政府对酒精消费的指导进行了比较。这项试验将在一个退伍军人群体中进行，他们通过英国退伍军人心理健康慈善机构“战斗压力”寻求帮助。招募、同意和数据收集将通过Drinks：Ration平台自动进行。主要结局是基线（第0天）和3个月随访（第84天）之间自我报告的每周饮酒量的变化，使用饮酒时间线随访进行测量。次要结局指标包括（1）基线至3个月随访（第84天）酒精使用障碍识别测试评分的变化和（2）基线至3个月随访（第84天）世界卫生组织生活质量-BREF评分的变化，以评估调整生命年的质量。过程评估指标包括（1）应用程序使用和（2）可用性评级，通过mHealth应用程序可用性调查问卷进行测量。还将在6个月随访（第168天）时重新评估主要和次要结局，以评估干预的长期获益，并将其报告为次要结局。研究将于2020年10月开始招募，预计需要12个月完成。研究结果将于2022年公布。这项研究评估了智能手机应用程序是否能有效地减少退伍军人群体自我报告的酒精消费量，这些退伍军人群体通过使用个性化消息传递和互动功能来对抗压力寻求帮助。这种创新的方法，如果成功的话，可以提供一种手段，提供一个低成本的健康促进方案，有可能达到大的群体，特别是那些谁是地理上分散，如军事人员。ClinicalTrials.gov NCT 04494594; https://clinicaltrials.gov/ct2/show/NCT04494594 PRR1-10.2196/19720
Alcohol misuse is higher in the UK Armed Forces than in the general population. Previous research has shown that interventions delivered via smartphones are efficacious in promoting self-monitoring of alcohol use, have utility in reducing alcohol consumption, and have a broad reach. This single-blinded randomized controlled trial (RCT) aims to assess the efficacy of a 28-day brief alcohol intervention delivered via a smartphone app (Drinks:Ration) in reducing weekly self-reported alcohol consumption between baseline and 3-month follow-up among veterans who drink at a hazardous or harmful level and receive or have received support for mental health symptoms in a clinical setting. In this two-arm, single-blinded RCT, a smartphone app that includes interactive features designed to enhance participants’ motivation and personalized messaging is compared with a smartphone app that provides only government guidance on alcohol consumption. The trial will be conducted in a veteran population that has sought help through Combat Stress, a UK veteran’s mental health charity. Recruitment, consent, and data collection will be carried out automatically through the Drinks:Ration platform. The primary outcome is the change in self-reported weekly alcohol consumption between baseline (day 0) and 3-month follow-up (day 84) as measured using the Time-Line Follow back for Alcohol Consumption. Secondary outcome measures include (1) change in the baseline to 3-month follow-up (day 84) Alcohol Use Disorder Identification Test score and (2) change in the baseline to 3-month follow-up (day 84) World Health Organization Quality of Life-BREF score to assess the quality of adjusted life years. Process evaluation measures include (1) app use and (2) usability ratings as measured by the mHealth App Usability Questionnaire. The primary and secondary outcomes will also be reassessed at the 6-month follow-up (day 168) to assess the longer-term benefits of the intervention, which will be reported as a secondary outcome. The study will begin recruitment in October 2020 and is expected to require 12 months to complete. The study results will be published in 2022. This study assesses whether a smartphone app is efficacious in reducing self-reported alcohol consumption in a veteran population that has sought help through Combat Stress using personalized messaging and interactive features. This innovative approach, if successful, may provide a means to deliver a low-cost health promotion program that has the potential to reach large groups, in particular those who are geographically dispersed, such as military personnel. ClinicalTrials.gov NCT04494594; https://clinicaltrials.gov/ct2/show/NCT04494594 PRR1-10.2196/19720